ClinicalTrials.gg
CompletedNCT07934134SIM-GBVUpdated Nov 12, 2026

Learning Through Observation or Participation in Gender-Based Violence Simulation: A Randomized Trial

An interventional study of High-Fidelity Simulation with Active Participation and Active Observational Learning in Gender Based Violence, Health Sciences and Undergraduate Nursing Education, sponsored by University of Barcelona. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Barcelona · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2025, registered Nov 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Gender-based violence is a widespread public health problem and a serious violation of human rights. Nurses play a key role in identifying and supporting women experiencing violence; however, nursing students often report feeling insufficiently prepared to address these situations in clinical practice. Although simulation-based learning is widely recommended for developing communication, assessment, and decision-making skills, evidence comparing active participation with structured observational learning in gender-based violence education remains limited.

This study aims to compare the effectiveness of active participation in a standardized patient simulation and structured observational learning on nursing students' knowledge of gender-based violence and their satisfaction with the learning experience.

A parallel-group randomized controlled trial will be conducted at a public university in Barcelona, Spain. A total of 122 first-year nursing students will be randomly assigned to either an active participation group or a structured observational learning group. Before the simulation experience, participants will complete the Multidimensional Scale of Dating Violence 2.0 to assess previous exposure to dating violence. Following a theoretical class session and a pre-briefing, students will engage in a high-fidelity simulation scenario involving a standardized patient experiencing gender-based violence. Participants in the intervention group will actively perform the simulation, while those in the control group will observe the scenario using a structured observation guide. Both groups will subsequently participate in the same facilitated debriefing session.

Knowledge acquisition will be assessed immediately before and after the intervention using a 14-item ad hoc knowledge checklist. Satisfaction with the simulation experience will be measured using the Spanish Satisfaction Scale Questionnaire with High-Fidelity Clinical Simulation (CS-SCAF). The study will evaluate changes in knowledge and satisfaction associated with active versus observational participation in simulation-based training on gender-based violence.

02

Conditions studied

  • Gender Based Violence
  • Health Sciences
  • Undergraduate Nursing Education
  • High Fidelity Simulation

Keywords

  • Gender-based violence
  • Nursing education
  • simulation-based learning
  • Observational learning
  • Standarized patient
  • Randomized controlled trial
03

In context

Lead sponsor

University of Barcelona is the lead sponsor of 100 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

First-year undergraduate nursing students enrolled at the University of Barcelona.

Attendance at the theoretical class session on gender-based violence. Ability to understand and communicate in Spanish. Provision of to participate in the study.

Exclusion criteria

Exclusion Criteria:

Failure to attend the simulation session or debriefing session. Incomplete pre-intervention or post-intervention assessments. Withdrawal of consent at any time during the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Active Participation Simulation

    Participants actively engaged in a high-fidelity simulation scenario involving a standardized patient portraying a woman experiencing gender-based violence. Following the simulation, participants attended a structured debriefing session.

    Behavioral: High-Fidelity Simulation with Active Participation

  • Other
    Active Observational Learning

    Participants observed the same high-fidelity simulation scenario using a structured observation guide and subsequently attended the same structured debriefing session as the intervention group.

    Behavioral: Active Observational Learning

Interventions

  • BehavioralHigh-Fidelity Simulation with Active Participation

    Students actively participated in a high-fidelity simulation scenario with a standardized patient portraying a woman experiencing gender-based violence. The intervention included a pre-briefing, active participation in the simulation, and a structured debriefing session.

  • BehavioralActive Observational Learning

    Students observed a high-fidelity simulation scenario involving a standardized patient experiencing gender-based violence using a structured observation guide. Following the observation, participants attended the same structured debriefing session.

06

What researchers measure

Primary outcomes

  1. Change in Knowledge of Gender-Based Violence

    Knowledge of gender-based violence assessed using a 14-item ad hoc knowledge checklist administered immediately before and immediately after the simulation-based learning experience. Higher scores indicate greater knowledge.

    Time frame: Immediately before the intervention and immediately after the intervention.

Secondary outcomes

  1. Satisfaction With the Simulation-Based Learning Experience

    Student satisfaction with the simulation-based learning experience assessed using the Spanish Satisfaction Scale Questionnaire with High-Fidelity Clinical Simulation (CS-SCAF).

    Time frame: Immediately after the intervention.

  2. Previous Exposure to Dating Violence

    Previous exposure to dating violence assessed using the Multidimensional Scale of Dating Violence 2.0 (MSDV 2.0).

    Time frame: Baseline (prior to the intervention).

07

Study locations

1 site
  • Facultat d'Infermeria. Campus Clínic i Bellvitge
    L'Hospitalet de Llobregat, Catalonia 08907, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 12, 2026
StartActual
Oct 1, 2025
Primary completionActual
Dec 30, 2025
CompletionActual
Jan 30, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934134
Responsible party
Marta Prats Arimon (Sara Sanchez Balcells, University of Barcelona) — Principal investigator
First posted
Nov 12, 2026
Start date
Oct 1, 2025
Primary completion
Dec 30, 2025
Completion
Jan 30, 2026
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion